Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-), and has spread to other parts of the body or nearby tissues (confirm with trial site for specific disease measurement requirements depending on which part of the trial applies).
- People in the dose escalation part who have received no more than one chemotherapy treatment for advanced or metastatic disease, have previously been treated with a type of targeted therapy called a CDK4/6 inhibitor, and have had any number of hormone therapy treatments.
- People in the dose expansion part who have received no more than one chemotherapy treatment for advanced or metastatic disease, no more than two lines of hormone therapy (with at least six months on that therapy before the cancer progressed), and no more than two courses of CDK4/6 inhibitor therapy (with at least six months on that therapy).
- People whose blood counts are within acceptable ranges, including white blood cell levels, platelet counts, and haemoglobin levels, without needing growth factors or transfusions to reach those levels (a red blood cell transfusion is allowed if it was given at least 14 days before joining the trial).
- People whose liver function test results are within acceptable ranges as determined by the trial site.
- People who are willing and able to give informed consent to participate.
- People who meet all study requirements in the opinion of the treating investigator.
Who may not be able to join:
- People who have a mutation in the RB1 (retinoblastoma) gene.
- People whose cancer has spread to internal organs and is causing noticeable symptoms.
- People who have a history of, or current signs of, cancer that has spread to the brain or central nervous system.
- People who have blood clotting problems or who are taking blood-thinning medications that would make injections of certain study medications (fulvestrant or LHRH agonist) unsafe.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeremy Barton, MD, Chief Medical Officer
Phone: 858-354-1814
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and Tolerability of BTX-9341; Part A: Number of Participants With Dose Limiting Toxicities (DLTs); Part A: Determine MTD/MED of BTX-9341 in monotherapy; Part A: Determine MTD/MED of BTX-9341 in combination therapy; Part B Combination Therapy: Objective Response (OR) rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.